α2-adrenoceptor antagonist (pKi values are 8.52, 8.00 and 9.17 for human α2A, α2B and α2C receptors respectively). Diastereomer Rauwolscine hydrochloride (Cat. No. 0891) also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 390.91. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.56 mL||12.79 mL||25.58 mL|
|5 mM||0.51 mL||2.56 mL||5.12 mL|
|10 mM||0.26 mL||1.28 mL||2.56 mL|
|50 mM||0.05 mL||0.26 mL||0.51 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Doxey et al (1984) Comparison of the α-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch.Pharmacol. 325 136 PMID: 6144048
Lalchandani et al (2002) Yohimbine dimers exhibiting selectivity for the human α2c-adrenoceptor subtype. J.Pharmacol.Exp.Ther. 303 979 PMID: 12438517
Redfern and Williams (1995) A re-evaluation of the role of α2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br.J.Pharmacol. 116 2081 PMID: 8640349
If you know of a relevant reference for Yohimbine hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Selective α2-adrenoceptor alpha2-adrenoceptor a2-adrenoceptor antagonist α2-Adrenergic alpha2-Adrenergic a2-adrenergic Receptors Adrenergic Alpha-2 Receptors
17 Citations for Yohimbine hydrochloride
Citations are publications that use Tocris products. Selected citations for Yohimbine hydrochloride include:
Delaney and Crane (2016) Presynaptic GABAB receptors reduce transmission at parabrachial synapses in the lateral central amygdala by inhibiting N-type calcium channels. Sci Rep 6 19255 PMID: 26755335
Kastman et al (2016) Nucleus incertus Orexin2 receptors mediate alcohol seeking in rats Neuropharmacology 110 82 PMID: 27395787
Gazarini et al (2015) PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation. Int J Neuropsychopharmacol 18 PMID: 25539509
Dudek et al (2015) A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. PLoS One 10 e0141327 PMID: 26506439
Scardochio et al (2015) The Effects of Electrical and Optical Stimulation of Midbrain Dopaminergic Neurons on Rat 50-kHz Ultrasonic Vocalizations. Front Behav Neurosci 9 331 PMID: 26696851
Soty et al (2015) A gut-brain neural circuit controlled by intestinal gluconeogenesis is crucial in metabolic health. Psychopharmacology (Berl) 4 106 PMID: 25685698
Phelps et al (2015) Psychopharmacological characterisation of the successive negative contrast effect in rats. Proc Natl Acad Sci U S A 232 2697 PMID: 25791190
Costello et al (2014) Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology 39 1843 PMID: 24513971
Ciccocioppo et al (2014) Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat. Neuropsychopharmacology 39 2601 PMID: 24863033
Drake et al (2014) The degree of acute descending control of spinal nociception in an area of primary hyperalgesia is dependent on the peripheral domain of afferent input. J Physiol 592 3611 PMID: 24879873
Corcoran et al (2014) Dual effects of 5-HT(1a) receptor activation on breathing in neonatal mice. Mol Metab 34 51 PMID: 24381267
Mondal et al (2013) Mechanism of ghrelin-induced gastric contractions in Suncus murinus (house musk shrew): involvement of intrinsic primary afferent neurons. PLoS One 8 e60365 PMID: 23565235
Ryan et al (2013) Relaxin-3/RXFP3 system regulates alcohol-seeking. Proc Natl Acad Sci U S A 110 20789 PMID: 24297931
Kim et al (2011) Icilin-evoked behavioral stimulation is attenuated by alpha2-adrenoceptor activation. Brain Res 1384 110 PMID: 21315691
Barnea et al (2008) The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A 105 64 PMID: 18165312
Maupoil et al (2007) Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1- and beta1-adrenoceptors. Br J Pharmacol 150 899 PMID: 17325650
Marchese et al (2003) Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 140 520 PMID: 12970091
Do you know of a great paper that uses Yohimbine hydrochloride from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.